Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Hong Kong
  4. Hong Kong Stock Exchange
  5. Ocumension Therapeutics
  6. Summary
    1477   KYG674111011

OCUMENSION THERAPEUTICS

(1477)
  Report
 SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   End-of-day quote. End-of-day quote Hong Kong Stock Exchange
12/02/2021 12/03/2021 12/06/2021 12/07/2021 12/08/2021 Date
16.5 16.48 15.68 15.84 16.2 Last
370500 225000 312000 631000 229000 Volume
+0.24% -0.12% -4.85% +1.02% +2.27% Change
Estimated financial data (e)
Sales 2021 85,1 M 13,4 M 13,4 M
Net income 2021 -438 M -69,0 M -69,0 M
Net cash position 2021 1 655 M 261 M 261 M
P/E ratio 2021 -13,6x
Yield 2021 -
Sales 2022 257 M 40,4 M 40,4 M
Net income 2022 -438 M -69,0 M -69,0 M
Net cash position 2022 1 069 M 169 M 169 M
P/E ratio 2022 -13,8x
Yield 2022 -
Capitalization 8 539 M 1 346 M 1 346 M
EV / Sales 2021 80,9x
EV / Sales 2022 29,1x
Nbr of Employees 187
Free-Float 46,3%
More Financials
Company
Ocumension Therapeutics is a China-based holding company principally involved in the discovering, developing and commercializing ophthalmic therapies. Its main products include OT-401 (YUTIQ), OT-1001 (ZERVIATE), OT-502 (DEXYCU), OT-301 (NCX 470), OT-101 and OT-202, among others. The Company conducts its businesses in the domestic market. 
Sector
Pharmaceuticals
Calendar
-
More about the company
Ratings of Ocumension Therapeutics
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
-
More Ratings
All news about OCUMENSION THERAPEUTICS
10/12OCUMENSION THERAPEUTICS : China Approves Clinical Trial of Ocumension Therapeutics Drug fo..
MT
10/12Ocumension Therapeutics Announces Approval Received for Clinical Trial of Class I New D..
CI
09/20Ocumension Therapeutics Reports Unaudited Consolidated Earnings Results for the Six Mon..
CI
09/15OCUMENSION THERAPEUTICS' : Phase 3 Clinical Trial Application for Eye Inflammation Treatme..
MT
09/14Ocumension Therapeutics Receives CDE Approval for Commencement of a Phase III Clinical ..
CI
08/25OCUMENSION THERAPEUTICS : Snaps Up Interests In Two Eye Drugs In China From Novartis
MT
08/25OCUMENSION THERAPEUTICS : Acquires all the Equity Interests in Two Ophthalmic Products Mai..
PR
08/23OCUMENSION THERAPEUTICS : Unit Buying Chinese Licenses for Ocular Itch Treatment for $35 M..
MT
08/20Ocumension Therapeutics Announces Interim Earnings Results for the 6 Months Ended 30 Ju..
CI
08/20OCUMENSION THERAPEUTICS : Announces 2021 Interim Results
PR
08/17Ocumension Therapeutics Announces the Group's Product, OT-502 Approves for Carrying Out..
CI
08/16Ocumension Therapeutics Issues Warrants to Nasdaq-Listed Drugmaker
MT
08/10OCUMENSION THERAPEUTICS : Notice of extraordinary general meeting
PU
08/02OCUMENSION THERAPEUTICS : Wins Regulatory Nod to Start Phase III Trial of Myopia Drug in U..
MT
08/02Ocumension Therapeutics MHRA Approval Received for Phase III Clinical Trial of OT-101 i..
CI
More news
News in other languages on OCUMENSION THERAPEUTICS
07/09La demande d'essai clinique de phase III d'Ocumension pour les gouttes oculaires est ac..
07/07Ocumension obtient le feu vert pour importer un médicament postopératoire dans la provi..
07/05Nicox recevra 2 millions de dollars d'Ocumension dans le cadre d'un accord de licence m..
07/05NICOX : Ocumension va payer un montant de 2 M$
07/05Vers l'infini et au-delà
More news
Chart OCUMENSION THERAPEUTICS
Duration : Period :
Ocumension Therapeutics Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends OCUMENSION THERAPEUTICS
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 4
Last Close Price 13,18 CNY
Average target price 26,58 CNY
Spread / Average Target 102%
EPS Revisions
Managers and Directors
Ye Liu Chief Executive Officer & Executive Director
Jian Ping Yang Finance Director
Lian Yong Chen Non-Executive Chairman
Chang Dong Liu Chief Scientific Officer
Dong Hong Chen Chief Medical Officer
Sector and Competitors
1st jan.Capi. (M$)
OCUMENSION THERAPEUTICS-40.00%1 316
JOHNSON & JOHNSON3.80%430 061
ROCHE HOLDING AG19.17%324 115
PFIZER, INC.39.85%290 297
NOVO NORDISK A/S70.26%250 392
ELI LILLY AND COMPANY45.17%222 215